Fumito Ito, MD, PhD, FACS

Surgical Oncology

Fumito Ito, MD, PhD, FACS

Fumito Ito, MD, PhD, joined the faculty of Roswell Park Comprehensive Cancer Center in 2015 and is an Associate Professor of Oncology in the Department of Surgical Oncology and the Center for Immunotherapy. He is also an Associate Professor of Surgery, Jacobs School of Medicine and Biomedical Sciences, State University of New York at Buffalo.

After earning his medical degree from the Shiga University, Japan, Dr. Ito completed his postgraduate training in Surgery at the Shiga University Hospital, Japan. Dr. Ito then completed a research fellowship in Tumor Immunology at the University of Michigan and earned his PhD from the Shiga University, Japan. From 2003 to 2010, Dr. Ito completed his surgery residency training at the University of Wisconsin and surgical oncology fellowship training at the Roswell Park Comprehensive Cancer Center. He then served as an Assistant Professor in the Department of Surgery at the University of Michigan before returning to the Roswell Park Comprehensive Cancer Center in 2015.

Dr. Ito is licensed by New York State and certified in General Surgery by the American Board of Surgery.

He has a significant clinical interest in melanoma, sarcoma, breast and gastrointestinal cancer. Dr. Ito’s research interests include the development of novel cancer immunotherapy using pluripotent stem cells, and the use of genome-engineering technology to augment anti-cancer responses, and the discovery of blood-based biomarkers to predict response and toxicity to immunotherapy.

Dr. Ito is a member of the American College of Surgeons, the Society of Surgical Oncology, the Central Surgical Association, the American Association for Cancer Research, the American Association of Immunologists, and the Society of Thermal Medicine.


Related Videos

Strategy for Overcoming Resistance to Immunotherapy Unleashes Power of Dendritic Cells Video

Strategy for Overcoming Resistance to Immunotherapy Unleashes Power of Dendritic Cells

Immune checkpoint inhibitor therapy, which activates T cells to kill tumor cells, is an effective way to treat some cancer types.